Chapter title |
Immune Suppression in Allogeneic Hematopoietic Stem Cell Transplantation.
|
---|---|
Chapter number | 544 |
Book title |
Pharmacology of Immunosuppression
|
Published in |
Handbook of experimental pharmacology, October 2021
|
DOI | 10.1007/164_2021_544 |
Pubmed ID | |
Book ISBNs |
978-3-03-105117-3, 978-3-03-105118-0
|
Authors |
Michniacki, Thomas F, Choi, Sung Won, Peltier, Daniel C, Michniacki, Thomas F., Peltier, Daniel C. |
Abstract |
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for high-risk hematologic disorders. There are multiple immune-mediated complications following allo-HSCT that are prevented and/or treated by immunosuppressive agents. Principal among these immune-mediated complications is acute graft-versus-host disease (aGVHD), which occurs when the new donor immune system targets host tissue antigens. The immunobiology of aGVHD is complex and involves all aspects of the immune system. Due to the risk of aGVHD, immunosuppressive aGVHD prophylaxis is required for nearly all allogeneic HSCT recipients. Despite prophylaxis, aGVHD remains a major cause of nonrelapse mortality. Here, we discuss the clinical features of aGVHD, the immunobiology of aGVHD, the immunosuppressive therapies used to prevent and treat aGVHD, how to mitigate the side effects of these immunosuppressive therapies, and what additional immune-mediated post-allo-HSCT complications are also treated with immunosuppression. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 24 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 3 | 13% |
Student > Doctoral Student | 3 | 13% |
Student > Ph. D. Student | 2 | 8% |
Researcher | 2 | 8% |
Unspecified | 2 | 8% |
Other | 0 | 0% |
Unknown | 12 | 50% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 4 | 17% |
Medicine and Dentistry | 3 | 13% |
Unspecified | 2 | 8% |
Immunology and Microbiology | 1 | 4% |
Unknown | 14 | 58% |